Serena Williams, the former tennis champion, has publicly shared her weight loss journey, revealing that she lost 31 pounds over eight months using GLP-1 weight-loss medication. Following challenges in losing weight after the births of her two daughters, Williams turned to the drug, specifically Zepbound, offered through the telehealth company Ro, which she now represents as a celebrity patient ambassador. Williams has emphasized that the medication is a tool that complements diet, exercise, and discipline, not a shortcut. Her involvement marks a notable shift as she is considered one of the first mainstream healthy figures to endorse GLP-1 drugs, which have been available via Ro since 2023. This endorsement comes amid broader discussions about the use and stigma of weight-loss drugs like Ozempic and Mounjaro. Williams' husband, Alexis Ohanian, is an investor in Ro. Her candidness aims to inspire others and reshape public discourse on weight management and obesity treatment. The GLP-1 class of drugs is gaining attention globally, with rising use in markets such as India and ongoing debates about safety, accessibility, and long-term health strategies. Williams has also addressed criticism and stigma associated with using such medications, advocating for a more informed and supportive approach to obesity care.